Product was Tg Therapeutics’s largest product and service line in fiscal 2025, bringing in $606.93M of $625.65M (97%).
| Product and Service | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|
| Product | $2.63M | $92.01M | $313.73M | $606.93M | |||
| License Revenue | $152.00K | $140.15M | $152.00K | $152.00K | |||
| Milestone | — | — | $12.50M | — | |||
| License | — | — | — | $9.36M | |||
| Royalty | — | — | $801.00K | $5.62M | |||
| Other Revenue | — | $1.50M | $1.82M | $3.59M | |||
| Total | $2.79M | $233.66M | $329.00M | $625.65M |
Tg Therapeutics brought in $625.65M from its five product and service lines in fiscal 2025, the year ended December 31, 2025. Tg Therapeutics regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $329.00M. Product was the largest at $606.93M (97.0%), ahead of License at $9.36M (1.5%) and Royalty at $5.62M (0.9%). The other two lines brought in $3.74M combined.
Tg Therapeutics began breaking out License in fiscal 2025, Royalty in fiscal 2024 and Other Revenue in fiscal 2023. Tg Therapeutics stopped reporting Milestone as a separate line after fiscal 2024, when it brought in $12.50M.
United States was Tg Therapeutics’s largest region in fiscal 2025, bringing in $594.11M of $606.93M (98%).
| Geography | FY 2025 |
|---|---|
| United States | $594.11M |
| International | $12.82M |
| Total | $606.93M |
Tg Therapeutics brought in $606.93M from its two regions in fiscal 2025, the year ended December 31, 2025. United States was the largest at $594.11M (97.9%), ahead of International at $12.82M (2.1%).
Tg Therapeutics (TGTX) reports its revenue by product and service and by geography. In fiscal 2025, Product was its largest product and service line, bringing in $606.93M (97.0% of the total), followed by License at $9.36M (1.5%).
Product was Tg Therapeutics' largest product and service line in fiscal 2025, bringing in $606.93M, or 97.0% of the $625.65M total across its five product and service lines.
United States was Tg Therapeutics' largest region in fiscal 2025, bringing in $594.11M, or 97.9% of the $606.93M total across its two regions.
Every figure comes from Tg Therapeutics' annual financial filings, as reported. Each line keeps the name Tg Therapeutics gives it, and years follow its fiscal calendar.
Tg Therapeutics' revenue by product and service goes back to fiscal 2019, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.